Dr. Barry R. Davis

powered by
COS Expertise®
University of Texas Health Science Center at Houston
School of Public Health
Biostatistics
ProfessorAppointed: 1992
University of Texas Health Science Center at Houston
School of Public Health
Coordinating Center for Clinical Trials
DirectorAppointed: 2003
University of Texas Health Science Center at Houston
School of Public Health
Biostatistics
DirectorAppointed: 2003
Professional Headshot of Barry R. Davis

Mailing Address

1200 Herman Pressler Street
E-809
Houston, Texas 77030
United States

Contact Information

Phone: (713) 500-9515
Fax: (713) 500-9530
barry.r.davis@uth.tmc.edu

Qualifications

Ph.D., Brown University, Applied Mathematics, 1982.
M.Sc., Brown University, Applied Mathematics, 1981.
M.D., University of California, San Diego, 1977.
B.S., Massachusetts Institute of Technology, Life Sciences, 1973.

Expertise and Research Interests

My research and expertise is in clinical trials. I am or have been a principal investigator or co-investigator in the Coordinating Centers for the following multi-center clinical trials: Systolic Hypertension in the Elderly Program (SHEP); Hypertension Detection and Follow-up Program (HDFP); Trial of Antihypertensive Interventions and Management (TAIM); Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP); Survival and Ventricular Enlargement--The Captopril Study (SAVE); Beta-BlockerHeart Attack Trial (BHAT); the Cholesterol and Recurrent Events Trial (CARE); the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT); and the Genetics of Hypertension Associated Treatments (GenHAT)). My research focuses on the the design, conduct, and analysis of clinical trials with specific attention to the interim monitoring of clinical trials.

Other Expertise

Academic Experience:
American College of Preventive Medicine, Fellow
American Heart Association, Council on Epidemiology Fellow
American Statistical Association Fellow
Outstanding Faculty Award, The University of Texas Health Science Center, 1992,1993, 1994, 1995, 1996
Peer Recognition for Outstanding Achievement in Sponsored Research, 1994 - ALLHAT Project - ''Largest Contract Ever Received by UT - Houston''
UTHHSC School of Public Health Dean's Teaching Excellence Award
The University of Texas Health Science Center, Nationally Recognized Honors in Research, 1996,2003
The University of Texas Health Science Center, Nationally Recognized Honors in Service, 1997, 1999, 2001
President, Society for Clinical Trials, 1999-2000
Chair, Biometrics Section, American Statistical Association, 2003

Committees:American Statistical Association - Membership Committee,Biometric Section Executive Committee
International Biometric Society - Regional Committee of ENAR 1997-1999; Council 2000-2001
Society for Clinical Trials - Board of Directors, 1997 Program Committee Chair, President-Elect, 1998-1999, President, 1999-2000.

Consultant for:
Baylor College of Medicine
Houston Department of Health & Human Services
Stehlin Foundation for Cancer Research
Cardiac Pacemakers, Inc.
UAW-Ford National Joint Committee on Health and Safety
Bristol-Myers Squibb
Krug Life Sciences;
National Aeronautics and Space Administration
G. D. Searle, Inc.
Bayer, Inc.
Merck, Inc.
Westat
SmithKline Beecham Pharmaceuticals
Eli Lilly and Company
Microsoft
Metrix Communications
TAP Pharmaceuticals

Editorial Reviewer:
American Journal of Epidemiology
American Journal of Hypertension
American Journal of Public Health
Annals of Epidemiology
Archivesof Ophthalmology
Biometrics
Chronobiology International
Controlled Clinical Trials
Circulation
Communications in Statistics
Journal of American Geriatric Society
Journal of American Statistical Association
The Lancet
Preventive Medicine

Editor/Co-Editor:
Journal of American Statistical Association, Associate Editor, SpecialBiopharmaceutical Section Edition
Associate Editor, Controlled Clinical Trials.

Review Committees:
National Heart, Lung, and Blood Institute
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and MusculoskeletalDiseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Eye Institute
National Institute on Aging
National Institute of Dental Research
Veterans Administration Cooperative Studies Program

DATA AND SAFETY MONITORING BOARD APPOINTMENTS:
Texas Children's Hospital:
Policy Advisory Committee, Clinical Trial to Evaluate Use of Alternate Day Steroids to Promote Growth
in Children with Crohn's Disease,1990-.

VA Cooperative Studies Operations Committee Data Monitoring Boards:
Study #300, Detection and Treatment of Influenza A in High Risk Ambulatory Patients, 1986-1990
Study #363, The VA HDL Intervention Trial (HIT), 1991-1998

National,Heart, Lung, and Blood Institute Data and Safety Monitoring Committees:Trial Of Nonpharmacologic Interventions in the Elderly (TONE), 1992-1995:
National Growth and Health Study (NGHS), 1992-1998
Magnesium in Coronary Arteries (MAGIC), 1998-

National Cancer Institute Data Monitoring Committees:
Intergroup Rhabdomyosarcoma Study, 1993-1998.

National Eye Institute Data Monitoring Committees:
Chair, Ocular Hypertension Treatment Study (OHTS), 1993-
Randomized Trial for Retinitis Pigmentosa, 1995-
Early Surgery for Congenital Esotropia (ESCET), 1997-
Studiesof Ocular Complications of AIDS (SOCA), 1998-

National Institute of Dental Research Data Monitoring Committees:
Children's Amalagam Trial (CAT), 1997-

G.D. Searle, Inc.;
Evaluation ofOral Xemilofibran in Controlling Thrombotic Events Trial (EXCITE), 1997-1999.

Eli Lilly and Company:
Monoxidine for Arterial Pressure (MAP), 1997-1999.

Miravant;
Photopoint Study in Age-Related Macular Degeneration, 1998-.

Parke-Davis:
ALLIANCE - Trial of Atrovastatin vs. Usual Care, 1998-.

National Aeronautics and Space Administration:
Prebreathe Reduction Protocol and Related Research, 2000 -.

Other Research Committees:
Vioxx Gastrointestinal Outcomes Research Study (VIGOR):
Steering Committee, 1999-.

Prevention of Restenosis with Tranilast and Its Outcomes: A Placebo-Controlled Trial (PRESTO):
Steering Committee, 1999-.

The Prospective Pravastatin Pooling (PPP) Project,1999-.

The World Health Organization-International Society of Hypertension Blood Pressure Lowering:
Treatment Trialists' Collaboration, 1999-.

Cholesterol Treatment Trialists' Collaboration, 1999-.

Future Research

We are a world leader in coordinating multicenter clinical trials in cardiovascular and eye disease. We plan to continue this research and to expand our horizons into genomics (see GenHAT).

Industrial Relevance

Research in clinical trials is highly relevant to pharmaceutical and other industries employing tradtional and new ways to conduct large-scale clinical trials. We have served as a Coordinating Center for industry-sponsored clinical trials and are always seeking new opportunities to do more.

Keywords

COS Keywords:

Biometry, Clinical Trial, Epidemiology, Hypertension, Preventive Medicine, Statistics.

Additional Terms:

Biometrics, Clinical Trials, Epidemiology, Hypertension, Myocardial Infarction, Preventive Medicine, Retinopathy of Prematurity, Statistics.

Memberships

American Association for the Advancement of Science
American College of Preventive Medicine
American Heart Association
American Public Health Association
American Statistical Association
Institute of Mathematical Statistics
International Biometrics Society
Sigma Xi, The Scientific Research Society
Society for Clinical Trials

Honors and Awards

2007, Fellow, Society for Clinical Trials, Clinical Trials
2004, President's Scholar Award for Research, UT Health Science Center, University of Texas Health Science Center at Houston
2003, Chair, Biometrics Section, American Statistical Association
2003, Nationally Recognized Honors in Research, University of Texas Health Science Center at Houston
2003, ALLHAT findings JAMA 12/18/2002 “one of the most cited recent papers in the field of Clinical Medicine', Thomson-ISI Web of Science
2002, ALLHAT selected as one of “Top Ten Achievements for 2002”, American Heart Association
2001, Nationally Recognized Honors in Service, University of Texas Health Science Center at Houston
1999-2000, President, Society for Clinical Trials, Clinical Trials
1999, Nationally Recognized Honors in Service, University of Texas - Houston Health Science Center, Service
1997, Nationally Recognized Honors in Service, University of Texas - Houston Health Science Center, Service
1996, Fellow, American Statistical Association, Statistics
1996, Nationally Recognized Honors in Research, University of Texas - Houston Health Science Center, Research
1994, Peer Recognition for Outstanding Achievement in Sponsored Research ALLHAT Project - 'Largest Contract Ever Received by UT - Houston', University of Texas - Houston Health Science Center, Research
1992, Fellow, American College of Preventive Medicine, Preventive Medicine
1992-2000, Outstanding Faculty Awards, University of Texas - Houston Health Science Center, Teaching, Service, Research
1990, Fellow, American Heart Association, Council on Epidemiology, Cardiovascular Epidemiology
1988-1989, Dean's Teaching Excellence List, The University of Texas School of Public Health, Teaching
1978-1979, University Fellowship, Brown University
1973-1977, Regents Scholar, University of California, San Diego

Previous Positions

1993, Consultant, Texas Heart Institute
1993, Research Scientist, Texas Heart Institute
1992, Professor, M.D. Anderson Cancer Center, Biomathematics
1983-1992, Assistant Professor, University of Texas School of Public Health, Biometry
1983-2000, Deputy Director, University of Texas Health Science Center at Houston, School of Public Health, Coordinating Center for Clinical Trials

Funding Received

  • NHLBI: Genetics of Hypertension Associated Treatments (GenHAT); Principal Investigator of Clinical Trials Center; 10%, $900,000, Aug 1, 1999 to Jul 31, 2004.
  • NHLBI; Principal Investigator and Director; 50% effort: Clinical Trials Center for Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), $102,000,000, Aug 1993 to Mar 2003.
  • NHLBI; Principal Investigator and Director; 50% effort: Clinical Trials Center for Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), $102,000,000, Aug 1993 to Mar 2003.
  • Cholesterol and Recurrent Events (CARE), 1989-1996; $2,516,685; 10% effort; Co-Investigator
  • Coordinating Center for the Systolic Hypertension in the Elderly Program (SHEP),1984-95; $8,833,384; 10% effort; Co-investigator, Deputy Director
  • Continuation of Trial of Antihypertensive Interventions and Management (COTAIM), 1988-95; $2,201,990; 10% effort; Principal Investigator, Director
  • Survival and Ventricular Enlargement: Effects of Captopril (SAVE), 1986-94; $1,486,782; 10% effort; Co-investigator
  • Cryotherapy Treatment of Retinopathy of Prematurity (CRYO-ROP) Follow-up, 1989-1995; $1,829,303; 10% effort; Co-Investigator

Publications

  • Garey KW, Lai D, Dao-Tran TK, Gentry LO, Hwang LY, Davis BR (Feb 2008) Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery., Antimicrobial agents and chemotherapy, 52 (2), 446-51 Abstract
  • Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT, Basile J, Wong ND, Whelton P, Dart RA, Thadani U (Feb 2008) Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent, Diabetes care, 31 (2), 353-60 Abstract
  • Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L (Jan 2008) Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Abstract
  • Wright JT, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, Basile JN, Black HR, Dart R, Gupta AK, Hamilton BP, Einhorn PT, Haywood LJ, Jafri SZ, Louis GT, Whelton PK, Scott CL, Simmons DL, Stanford C, Davis BR (Jan 2008) Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)., Archives of internal medicine, 168 (2), 207-17 Abstract
  • Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK (Jan 2008) Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension., JAMA : the journal of the American Medical Association, 299 (3), 296-307 Abstract
  • Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M (Jan 2008) Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease., 117 (2), 163-168 Abstract
  • Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C (Jan 2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis., Lancet, 371 (9607), 117-25 Abstract
  • Lynch AI, Arnett DK, Davis BR, Boerwinkle E, Ford CE, Eckfeldt JH, Leiendecker-Foster C (Nov 2007) Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study., Annals of human genetics, 71 (Pt 6), 735-45 Abstract
  • Barzilay JI, Cutler JA, Davis BR (May 2007) Antihypertensive medications and risk of diabetes mellitus., Current opinion in nephrology and hypertension, 16 (3), 256-60 Abstract
  • Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S (May 2007) Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system., Journal of hypertension, 25 (5), 951-8 Abstract
  • Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH (Apr 2007) Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study., The pharmacogenomics journal, 7 (2), 112-22 Abstract
  • Maitland-van der Zee AH, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, Miller MB, Klungel OH, Ford CE, Eckfeldt JH (Jan 2007) Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study., American heart journal, 153 (1), 54-8 Abstract
  • Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR (Jan 2007) The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis., American heart journal, 153 (1), 42-53 Abstract
  • Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J (Nov 2006) Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHA, Archives of internal medicine, 166 (20), 2191-201 Abstract
  • Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL (Sep 2006) Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)., Journal of clinical hypertension (Greenwich, Conn.), 8 (9), 649-56; quiz 657-8 Abstract
  • Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT (Sep 2006) Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial., Hypertension, 48 (3), 374-84 Abstract
  • Rahman M, Nwachuku C, Whelton P, Probstfield J, Davis BR (Jun 2006) Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens. 2005 Jun;18(6):744-9., American journal of hypertension : journal of the American Society of Hypertension, 19 (6), 656-7 Abstract
  • Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R (May 2006) Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial., Circulation, 113 (18), 2201-10 Abstract
  • Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (Oct 2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins., Lancet, 366 (9493), 1267-78 Abstract
  • Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, ALLHAT Collaborative Research Group, Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)., Archives of Internal Medicine, 165(12), 1401-9, Jun 2005 Abstract
  • Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S, Blood Pressure Lowering Treatment Trialists' Collaboration, Effects of Different Blood Pressure-lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials., Archives of Internal Medicine, 165(12), 1410-9, Jun 2005 Abstract
  • Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S (Jun 2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials., Archives of internal medicine, 165 (12), 1410-9 Abstract
  • Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH (Jun 2005) Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study., Circulation, 111 (25), 3374-83 Abstract
  • Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB, ALLHAT Collaborative Research Group, Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril., Jama : the Journal of the American Medical Association, 293(13), 1595-608, Apr 2005 Abstract
  • Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T, Renal Outcomes in High-risk Hypertensive Patients Treated With An Angiotensin-converting Enzyme Inhibitor Or a Calcium Channel Blocker Vs A Diuretic: a Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attac, Archives of Internal Medicine, 165(8), 936-46, Apr 2005 Abstract
  • Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, SHEP Collaborative Research Group, Long-term Effect of Diuretic-based Therapy on Fatal Outcomes in Subjects With Isolated Systolic Hypertension With and Without Diabetes., The American Journal of Cardiology, 95(1), 29-35, Jan 2005 Abstract
  • Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR, Wu X, Dietary Carotenoids and Genetic Instability Modify Bladder Cancer Risk., The Journal of Nutrition, 134(12), 3362-9, Dec 2004 Abstract
  • Best PJ, Berger PB, Davis BR, Grines CL, Sadeghi HM, Williams BA, Willerson JT, Granett JR, Holmes DR Jr, PRESTO Investigators, Impact of Mild Or Moderate Chronic Kidney Disease on the Frequency Of Restenosis: Results From the PRESTO Trial., Journal of the American College of Cardiology, 44(9), 1786-91, Nov 2004 Abstract
  • Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black H, Imputing Gene-treatment Interactions When the Genotype Distribution Is Unknown Using Case-only and Putative Placebo Analyses--a New Method For the Genetics of Hypertension Associated Treatment (GenHAT) Study., Statistics in Medicine, 23(15), 2413-27, Aug 2004 Abstract
  • Kenchaiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, Steingart RM, Brown EJ Jr, Lamas GA, Gordon D, Bernstein V, Pfeffer MA, Survival and Ventricular Enlargement Trial, Antecedent Hypertension and the Effect of Captopril on the Risk of Adverse Cardiovascular Outcomes After Acute Myocardial Infarction With Left Ventricular Systolic Dysfunction: Insights From the Survival And Ventricular Enlargement Tria, American Heart Journal, 148(2), 356-64, Aug 2004 Abstract
  • Davis BR, Furberg CD, Wright JT Jr, Cutler JA, Whelton P, ALLHAT Collaborative Research Group, ALLHAT: Setting the Record Straight., Annals of Internal Medicine, 141(1), 39-46, Jul 2004 Abstract
  • Kao J, Tobis J, McClelland RL, Heaton MR, Davis BR, Holmes DR Jr, Currier JW, Investigators in the Prevention of Restenosis With Tranilast and Its Outcomes Trial, Relation of Metformin Treatment to Clinical Events in Diabetic Patients Undergoing Percutaneous Intervention., The American Journal of Cardiology, 93(11), 1347-50, A5, Jun 2004 Abstract
  • Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, Levey AS, Nwachuku C, Pressel S, Reisin E, Walworth C, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group, The Prevalence of Reduced Glomerular Filtration Rate in Older Hypertensive Patients and Its Association With Cardiovascular Disease: a Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial., Archives of Internal Medicine, 164(9), 969-76, May 2004 Abstract
  • Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC Jr, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JN, Ft F., Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study, J Clin Hypertens, 6(3), 116-125, 6 Mar 2004
  • Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr., Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, Circulation, 109(4), 476-480, 3 Feb 2004
  • Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr, Outcomes in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention in the Current Era: a Report From the Prevention Of REStenosis With Tranilast and Its Outcomes (PRESTO) Trial., Circulation, 109(4), 476-80, Feb 2004 Abstract
  • Dickersin K, Davis BR, Dixon DO, George SL, Hawkinse BS, Lachin J, Peduzzi P, Pocock S, Society for Clinical Trials (2004) The Society for Clinical Trials supports United States legislation mandating trials registration, Clin Trials, 1 (5), 417-20
  • Davis BR, Wright JT Jr, Cutler JA, Angiotensin-converting-enzyme inhibitors and diuretics for hypertension, The New England Journal of Medicine, 349(1), 90-3; author reply 9, July 2003 Abstract
  • Halabi S, Wun CC, Davis BR, Analysis of survival data with missing measurements of a time-dependent binary covariate, Journal of Biopharmaceutical Statistics, 13(2), 253-70, May 2003 Abstract
  • Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, ALLHAT Collaborative Research Group, Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), Journal of Clinical Hypertension (greenwich, Conn.), 4(6), 393-405, 2002 Abstract
  • Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JJ, Popma J, King SB 3rd, Lincoff AM, Tcheng JE, Chan R, Granett JR, Poland M, Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, Circulation, 106(10), 1243-50, September 2002 Abstract
  • Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E, Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project, Circulation, 105(20), 2341-6, May 2002 Abstract
  • Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, Shepherd J, Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project, European Heart Journal, 23(3), 207-15, February 2002 Abstract
  • Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H, Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study, The Pharmacogenomics Journal, 2(5), 309-17, 2002 Abstract
  • Wright JT Jr, Cushman WC, Davis BR, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Pressel S, Leenen FH, Frolkis J, Letterer R, Walsh S, Tobin JN, Deger GE, ALLHAT Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience, Controlled Clinical Trials, 22(6), 659-73, December 2001 Abstract
  • Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, Farber M, Payne G, Probstfield J, Ward H, ALLHAT Research Group, Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Controlled Clinical Trials, 22(6), 674-86, December 2001 Abstract
  • Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC Jr, Ciocon JO, Sweeney ME, Randall OS, Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Diabetes Care, 24(4), 654-8, April 2001 Abstract
  • Pressel SL, Davis BR, Wright J et al., Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Controlled Clinical Trials, 22(1), 29-41, February 2001
  • Lai D, Moye LA, Davis BR, Brown LE, Sacks FM, Brownian motion and long-term clinical trial recruitment, Journal of Statistical Planning and Inference, 93, 230-246, 2001
  • Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SC, Shepherd J for the PPP Investigators, Reduction of stroke events with pravastatin - The Prospective Pravastatin Pooling (PPP) Project, Circulation, 103, 387-392, 2001
  • Fromm R, Meyer D, Zimmerman J, Boudreaux A, Wun CC, Smalling R, Davis B Habib G, Roberts R. ., A double-blind, multicentered study comparing the accuracy of diagnostics markers to predict short- and long-term clinical events and their utility in patients presenting with chest pain, Clinical Cardiology, 24, 516-520, 2001
  • Blood Pressure Lowering Treatment Trialists' Collaboration., Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials, Lancet, 355, 1955-1964, 2001
  • Cryotherapy for Retinopathy of Prematurity Cooperative Group., Effect of retinal ablative therapy for threshold retinopathy of prematurity: Results of Goldmann perimetry at age 10 years, Archives of Ophthalmology, 119, 1120-1125, 2001
  • Cryotherapy for Retinopathy of Prematurity Cooperative Group., Contrast sensitivity at age 10 years in children who had threshold retinopathy of prematurity, Archives of Ophthalmology, 119, 1129-1133, 2001
  • Cryotherapy for Retinopathy of Prematurity Cooperative Group., Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Ophthalmological outcomes at 10 years, Archives of Ophthalmology, 119, 1110-1118, 2001
  • Bombardier C, Lane L, Reisin A, Shapiro D, Burgos-Vargas R, Davis B, et al., Bombardier C, Lane L, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, New England Journal of Medicine, 343, 1520-1528, November 2000
  • Perry HM Jr, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, Kuller L, Pressel S, Stamler J, Probstfield JL, Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP), JAMA, 284(4), 465-71, July 2000 Abstract
  • Wassertheil-Smoller S, Fann C, Allman RM, Black HR, Camel GH, Davis B, Masaki K, Pressel S, Prineas RJ, Stamler J, Vogt TM, Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group, Archives of Internal Medicine, 160(4), 494-500, February 2000 Abstract
  • Lai, D, Davis BR, Hardy RJ, Fractional Brownian motion and clinical trials, Journal of Applied Statistics, 27, 103-108, 2000
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 283, 1967-1975, 2000
  • Blood Pressure Lowering Treatment Trialists' Collaboration, Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials, Lancet, 355, 1955-1964, 2000
  • Amos CI, Gu XJ, Chen JF, Davis BR, Least squares estimation of variance components for linkage, Genetic Epidemiology, 19 (Suppl 1), S1-S7, 2000
  • Domanski MJ, Davis BR, Pfeffer MA, Kastantin M, Mitchell GF, Isolated systolic hypertension : prognostic information provided by pulse pressure., Hypertension, 34(3), 375-80, September 1999 Abstract
  • Flaker GC, Warnica JW, Sacks FM, Moye LA, Davis BR, Rouleau JL, Webel RR, Pfeffer MA, Braunwald E, Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators, Journal of the American College of Cardiology, 34(1), 106-12, July 1999 Abstract
  • Stehlin JS, Giovanella BC, Natelson EA, De Ipolyi PD, Coil D, Davis B, Wolk D, Wallace P, Trojacek A, A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer, International Journal of Oncology, 14(5), 821-31, May 1999 Abstract
  • Zimmerman J, Fromm R, Meyer D, Boudreaux A, Wun CC, Smalling R, Davis B, Habib G, Roberts R, Diagnostic marker cooperative study for the diagnosis of myocardial infarction, Circulation, 99(13), 1671-7, April 1999 Abstract
  • Wittes J, Lakatos E, Black D, Geraci B, Davis B, Moye L, Probstfield J, Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program, Controlled Clinical Trials, 20(2), 121-32, April 1999 Abstract
  • The Light-ROP Cooperative Group, The design of the multicenter study of light reduction in retinopathy, Journal of Pediatric Ophthalmology and Strabismus, 36, 257-263, 1999
  • Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E, Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators, Circulation, 99(2), 216-23, Jan 1999 Abstract
  • Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E, Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators [see comments], Circulation, 99(2), 216-23, Jan 1999 Abstract
  • Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and, Circulation, 98(23), 2513-9, December 1998 Abstract
  • Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E, Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial, Annals of Internal Medicine, 129(9), 681-9, November 1998 Abstract
  • Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E, Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events \(CARE\) trial., Annals of Internal Medicine, 129(9), 681-9, 1 Nov 1998 Abstract
  • Repka M X, Summers C G, Palmer E A, Dobson V, Tung B, Davis B, The incidence of ophthalmologic interventions in children with birth weights less than 1251 grams. Results through 5 1/2 years. Cryotherapy for Retinopathy of Prematurity Cooperative Group., Ophthalmology, 105(9), 1621-7, September 1998 Abstract
  • Davis BR, Vogt T, Frost PH, Burlando A, Cohen J, Wilson A, Brass LM, Frishman W, Price T, Stamler J, Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group, Stroke, 29(7), 1333-40, July 1998 Abstract
  • Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WA, Fielder AR, Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group [see comments], New England Journal of Medicine, 338(22), 1572-6, May 1998 Abstract
  • Savage P J, Pressel S L, Curb J D, Schron E B, Applegate W B, Black H R, Cohen J, Davis B R, Frost P, Smith W, Gonzalez N, Guthrie G P, Oberman A, Rutan G, Probstfield J L, Stamler J, Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic H, Archives of Internal Medicine, 158(7), 741-51, 13 Apr 1998 Abstract
  • Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E, Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial, Circulation, 97(15), 1446-52, April 1998 Abstract
  • Hager W D, Davis B R, Riba A, Moye L A, Wun C C, Rouleau J L, Lamas G A, Pfeffer M A, Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventr, American Heart Journal, 135(3), 406-13, March 1998 Abstract
  • Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Loweri, Journal of Hypertension, 16(2), 127-37, February 1998 Abstract
  • Fuller LM, Mirza NQ, Palmer JL, Davis BR, Ha CS, Rodriguez MA, Hagemeister FB, Cabanillas F, McLaughlin P, Butler JJ, North LB, Martin RG, Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs., International Journal of Radiation Oncology, Biology, Physics, 40(2), 377-86, Jan 1998 Abstract
  • Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB, Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group, Jama, 278(3), 212-6, July 1997 Abstract
  • Hardy RJ, Palmer EA, Schaffer DB, Phelps DL, Davis BR, Cooper CJ, Outcome-based management of retinopathy of prematurity. Multicenter Trial of Cryotherapy for Retinopathy of prematurity Cooperative Group, Journal of Aapos, 1(1), 46-54, March 1997 Abstract
  • Proschan M, Davis B, Cutler J, Ford C, Furberg C, Grimm R, Oparil S, ALLHAT and calcium channel blockers. ALLHAT Research Group, American Journal of Hypertension, 10(1), 142-3, January 1997 Abstract
  • Proschan M, Davis B, Cutler J, Ford C, Furberg C, Grimm R, Oparil S, ALLHAT and calcium channel blockers. ALLHAT Research Group [letter; comment], American Journal of Hypertension, 10(1), 142-3, January 1997 Abstract
  • Curb J D, Pressel S L, Cutler J A, Savage P J, Applegate W B, Black H, Camel G, Davis B R, Frost P H, Gonzalez N, Guthrie G, Oberman A, Rutan G H, Stamler J, Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperat, Jama, 276(23), 1886-92, 18 Dec 1996 Abstract
  • Moye LA, Davis BR, Sacks F, Cole T, Brown L, Hawkins CM, Decision rules for predicting future lipid values in screening for a cholesterol reduction clinical trial, Controlled Clinical Trials, 17(6), 536-46, December 1996 Abstract
  • Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP Jr, Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J, Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP), Circulation, 94(10), 2381-8, November 1996 Abstract
  • Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, New England Journal of Medicine, 335(14), 1001-9, October 1996 Abstract
  • Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators [see comments], New England Journal of Medicine, 335(14), 1001-9, October 1996 Abstract
  • Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP, Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J, Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program, Circulation, 94(1), 26-34, July 1996 Abstract
  • Wilt TJ, Davis BR, Meyers DG, Rouleau JL, Sacks FM, Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Rec, Angiology, 47(6), 533-41, June 1996 Abstract
  • Whelton PK, Williamson JD, Louis GT, Davis BR, Cutler JA, Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack, Clinical and Experimental Hypertension, 18(3-4), 569-79, 1996 Abstract
  • Quinn GE, Dobson V, Barr CC, Davis BR, Palmer EA, Robertson J, Summers CG, Trese MT, Tung B, Visual acuity of eyes after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. The Cryotherapy for Retinopathy of Prematurity Cooperative Group, Ophthalmology, 103(4), 595-600, April 1996 Abstract
  • Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM, Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group, American Journal of Hypertension, 9(4 Pt 1), 342-60, April 1996 Abstract
  • Quinn GE, Dobson V, Barr CC, Davis BR, Palmer EA, Robertson J, Summers CG, Trese MT, Tung B, Visual acuity of eyes after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. The Cryotherapy for Retinopathy of Prematurity Cooperative Group [see comments], Ophthalmology, 103(4), 595-600, April 1996 Abstract
  • Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM, Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group [see comments], American Journal of Hypertension, 9(4 Pt 1), 342-60, April 1996 Abstract
  • Wassertheil-Smoller S, Applegate WB, Berge K, Chang CJ, Davis BR, Grimm R Jr, Kostis J, Pressel S, Schron E, Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systoloc Hypertension in the elderly), Archives of Internal Medicine, 156(5), 553-61, March 1996 Abstract
  • Blaufox MD, Middleton ML, Bongiovanni J, Davis BR, Cost efficacy of the diagnosis and therapy of renovascular hypertension, Journal of Nuclear Medicine, 37(1), 171-7, January 1996 Abstract
  • Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J, Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP), American Journal of Hypertension, 8(12 Pt 1), 1147-53, December 1995 Abstract
  • Hartley L H, Flaker G, Basta L, Menapace F, Goldman S, Davis B, Hamm P, Lamas G, Moye L, Wun C C, et al, Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril., American Journal of Cardiology, 76(12), 857-60, 1 Nov 1995 Abstract
  • Dobson V, Quinn GE, Saunders RA, Spencer R, Davis BR, Risser J, Palmer EA, Grating visual acuity in eyes with retinal residua of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group, Archives of Ophthalmology, 113(9), 1172-7, September 1995 Abstract
  • Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, et al, Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators, Circulation, 90(4), 1731-8, October 1994 Abstract
  • Davis B R, Oberman A, Blaufox M D, Wassertheil-Smoller S, Zimbaldi N, Kirchner K, Wylie-Rosett J, Langford H G, Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension. TAIM Research Group. Trial of Antihypertens, American Journal of Hypertension, 7(10 Pt 1), 926-32, October 1994 Abstract
  • Davis BR, Hardy RJ, Data monitoring in clinical trials: the case for stochastic curtailment, Journal of Clinical Epidemiology, 47(9), 1033-42, September 1994 Abstract
  • Moye L A, Pfeffer M A, Wun C C, Davis B R, Geltman E, Hayes D, Farnham D J, Randall O S, Dinh H, Arnold J M, et al, Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study., European Heart Journal, 15 Suppl B, 2-8; discussion 26-3, May 1994 Abstract
  • Moye LA, Davis BR, Hawkins CM, Probstfield JL, Conclusions and implications of the systolic hypertension in the elderly program, Clinical and Experimental Hypertension, 15(6), 911-24, November 1993 Abstract
  • Wassertheil-Smoller S, Davis BR, Breuer B, Chang CJ, Oberman A, Blaufox MD, Differences in precision of dietary estimates among different population subgroups, Annals of Epidemiology, 3(6), 619-28, November 1993 Abstract
  • Davis B R, Wittes J, Pressel S, Berge K G, Hawkins C M, Lakatos E, Moye L A, Probstfield J L, Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP)., Controlled Clinical Trials, 14(5), 350-61, October 1993 Abstract
  • Davis B R, Blaufox M D, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler J A, Kirchner K, Langford H G, Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension., Archives of Internal Medicine, 153(15), 1773-82, 9 Aug 1993 Abstract
  • Wylie-Rosett J, Wassertheil-Smoller S, Blaufox M D, Davis B R, Langford H G, Oberman A, Jennings S, Hataway H, Stern J, Zimbaldi N, Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention., Journal of The American Dietetic Association, 93(4), 408-15, April 1993 Abstract
  • Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group, Hypertension, 21(3), 335-43, March 1993 Abstract
  • Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group [see comments], Hypertension, 21(3), 335-43, March 1993 Abstract
  • Moye LA, Davis BR, Hawkins CM, Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint, Statistics in Medicine, 11(13), 1705-17, September 1992 Abstract
  • Coil DR, Giovanella BC, Greeff PJ, Stehlin JS, Davis BR, An experimental model for the study of thermochemotherapy in vivo, Anticancer Research, 12(5), 1363-71, 1992 Abstract
  • Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigat, New England Journal of Medicine, 327(10), 669-77, September 1992 Abstract
  • Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigat, New England Journal of Medicine, 327(10), 669-77, September 1992 Abstract
  • Loewy JW, Kapadia AS, Hsi B, Davis BR, Statistical methods that distinguish between attributes of assessment: prolongation of life versus quality of life, Medical Decision Making, 12(2), 83-92, 1992 Abstract
  • Davis B R, Oberman A, Blaufox M D, Wassertheil-Smoller S, Hawkins C M, Cutler J A, Zimbaldi N, Langford H G, Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group., Hypertension, 19(4), 393-9, April 1992 Abstract
  • Blaufox M D, Lee H B, Davis B, Oberman A, Wassertheil-Smoller S, Langford H, Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy., Jama, 267(9), 1221-5, 4 Mar 1992 Abstract
  • Quinn G E, Dobson V, Repka M X, Reynolds J, Kivlin J, Davis B, Buckley E, Flynn J T, Palmer E A, Development of myopia in infants with birth weights less than 1251 grams. The Cryotherapy for Retinopathy of Prematurity Cooperative Group., Ophthalmology, 99(3), 329-40, March 1992 Abstract
  • Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J, The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension, Archives of Internal Medicine, 152(1), 131-6, January 1992 Abstract
  • Wassertheil-Smoller S, Oberman A, Blaufox M D, Davis B, Langford H, The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life [see comments], American Journal of Hypertension, 5(1), 37-44, January 1992 Abstract
  • Applegate WB, Davis BR, Black HR, Smith WM, Miller ST, Burlando AJ, Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort, Journal of the American Geriatrics Society, 39(11), 1057-64, November 1991 Abstract
  • Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative, Jama, 265(24), 3255-64, June 1991 Abstract
  • Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative, Jama, 265(24), 3255-64, June 1991 Abstract
  • Wassertheil-Smoller S, Blaufox M D, Oberman A, Davis B R, Swencionis C, Knerr M O, Hawkins C M, Langford H G, Effect of antihypertensives on sexual function and quality of life: the TAIM Study [see comments], Annals of Internal Medicine, 114(8), 613-20, 15 Apr 1991 Abstract
  • Palmer EA, Hardy RJ, Davis BR, Stein JA, Mowery RL, Tung B, Phelps DL, Schaffer DB, Flynn JT, Phillips CL, Operational aspects of terminating randomization in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group, Controlled Clinical Trials, 12(2), 277-92, April 1991 Abstract
  • Hardy R J, Davis B R, Palmer E A, Tung B, Statistical considerations in terminating randomization in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group., Controlled Clinical Trials, 12(2), 293-303, April 1991 Abstract
  • Wittes J, Davis B, Berge K, Cohen JD, Grimm RH Jr, Hawkins CM, Kuller L, Systolic Hypertension of the Elderly Program (SHEP). Part 10: Analysis, Hypertension, 17(3 Suppl), II162-7, March 1991 Abstract
  • Borhani NO, Applegate WB, Cutler JA, Davis BR, Furberg CD, Lakatos E, Page L, Perry HM, Smith WM, Probstfield JL, Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design, Hypertension, 17(3 Suppl), II2-15, March 1991 Abstract
  • Hall WD, Davis BR, Frost P, Hoffmeier M, O'Brien JE, Pace S, Page L, Schneider KA, Stamler J, Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics, Hypertension, 17(3 Suppl), II102-22, March 1991 Abstract
  • Langford H G, Davis B R, Blaufox D, Oberman A, Wassertheil-Smoller S, Hawkins M, Zimbaldi N, Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group., Hypertension, 17(2), 210-7, February 1991 Abstract
  • Quinn G E, Dobson V, Barr C C, Davis B R, Flynn J T, Palmer E A, Robertson J, Trese M T, Visual acuity in infants after vitrectomy for severe retinopathy of prematurity [published erratum apppears in Ophthalmology 1991 Jul;98(7):1005], Ophthalmology, 98(1), 5-13, January 1991 Abstract
  • Cooper S P, Ford C E, Hardy R J, Davis B R, Hawkins C M, Labarthe D R, Results of trials reporting a J-shaped relation between achieved blood pressure and incidence of coronary heart disease, American Journal of Hypertension, 3(9), 733-4, September 1990 Abstract
  • Cooper S P, Ford C E, Hardy R J, Davis B R, Hawkins C M, Labarthe D R, Results of trials reporting a J-shaped relation between achieved blood pressure and incidence of coronary heart disease [letter; comment], American Journal of Hypertension, 3(9), 733-4, September 1990 Abstract
  • Ramirez G, Grimes RM, Annegers JF, Davis BR, Slater CH, Occupational physical activity and other risk factors for preterm birth among US Army primigravidas, American Journal of Public Health, 80(6), 728-30, June 1990 Abstract
  • Oberman A, Wassertheil-Smoller S, Langford H G, Blaufox M D, Davis B R, Blaszkowski T, Zimbaldi N, Hawkins C M, Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status, Annals of Internal Medicine, 112(2), 89-95, 15 Jan 1990 Abstract
  • Oberman A, Wassertheil-Smoller S, Langford H G, Blaufox M D, Davis B R, Blaszkowski T, Zimbaldi N, Hawkins C M, Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status [see comments], Annals of Internal Medicine, 112(2), 89-95, 15 Jan 1990 Abstract
  • Wassertheil-Smoller S, Langford H G, Yamori Y, Blaufox M D, Oberman A, Davis B, Nara Y, Wylie-Rosett J, Zimbaldi N, Estimation of protein intake: comparison of dietary assessment and urinary excretion., Journal of Cardiovascular Pharmacology, 16 Suppl 8, S28-31, 1990 Abstract
  • Davis B R, Blaufox M D, Hawkins C M, Langford H G, Oberman A, Swencionis C, Wassertheil-Smoller S, Wylie-Rosett J, Zimbaldi N, Trial of antihypertensive interventions and management. Design, methods, and selected baseline results., Controlled Clinical Trials, 10(1), 11-30, March 1989 Abstract
  • Eason SL, Petersen NJ, Suarez-Almazor M, Davis B, Collins TC, Diabetes mellitus, smoking, and the risk for asymptomatic peripheral arterial disease: whom should we screen?, The Journal of the American Board of Family Practice / American Board of Family Practice, 18 (5), 355-61 Abstract

Profile Details

Last Updated: 2/12/2008

COS Expertise ID #303571
Reference this profile directly: http://myprofile.cos.com/davisb71